Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX) will present a company update at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will cover Anixa's recent achievements, including the initiation of a clinical trial for its CAR-T based ovarian cancer treatment. The on-demand presentation starts at 7:00 a.m. ET on May 24, 2022, and can be accessed through a provided webcast link. A replay will be available for 90 days. Anixa focuses on cancer therapies and infectious diseases, collaborating with top medical institutions to develop innovative treatments.
- None.
- None.
SAN JOSE, Calif., May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Hybrid Conference).
The presentation will provide an overview of Anixa's business and highlight recent corporate achievements, including the recent initiation of the clinical trial of Anixa's CAR-T based ovarian cancer therapeutic program.
Details of Anixa's presentation are as follows:
Event: H.C. Wainwright Global Investment Conference
Date & Time: On demand, beginning 7:00 a.m. ET, Tuesday, May 24, 2022
Webcast link: https://journey.ct.events/view/974d69c8-112b-4db8-b4ba-6c8e97bb27b3
A replay of the presentation will be available for 90 days at the link above or by visiting the Investors section of Anixa's website at https://ir.anixa.com/events.
Anixa management will also be available for one-on-one meetings throughout the conference. Please contact your representative at H.C. Wainwright to request a meeting.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contacts
Company Contact:
Mike Catelani
President
mcatelani@anixa.com
408-708-9808
Investors:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
646-751-4363
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-2022-hc-wainwright-global-investment-conference-301540664.html
SOURCE Anixa Biosciences, Inc.
FAQ
What will Anixa Biosciences present at the H.C. Wainwright Global Investment Conference?
When is Anixa's presentation at the H.C. Wainwright Global Investment Conference scheduled?
How can I access the Anixa Biosciences presentation?
What are some of Anixa's recent achievements mentioned in the press release?
What is the focus of Anixa Biosciences?
